Teva pulls back, but analysts aren’t sure it’s a buy-the-dip setup

Healthcare stocks are increasingly being floated as potential leaders of the market’s next leg, especially if investors rotate out of crowded AI trades. But not every pharma name is expected to see a straight line higher from here.

For companies like Teva Pharmaceutical Industries Ltd., the outlook blends sector-wide opportunity with company-specific hurdles.

After more than doubling over the past year, shares have cooled in the lower $30s range in recent days. The rally pause comes as investors weigh pipeline progress against balance sheet and valuation risks.

Signs of momentum persist

Teva recently secured a $400 million, four-year financing agreement with Blackstone Life Sciences to advance duvakitug, its Phase III treatment for ulcerative colitis and Crohn’s disease. The drug targets a protein linked to IBD-related symptoms like inflammation and fibrosis, which affect millions globally.

Investors are watching a few key indicators:

• Blackstone funding reduces upfront risk while preserving upside potential
• Co-development with Sanofi reduces the cost and execution burden
• FDA acceptance of a new olanzapine injectable adds to Teva’s market depth
• Q4 EPS came in at $0.96 vs. $0.65 expected by analysts
• Revenue growth came in at 11.4% YoY and forward P/E guidance is around 11

Toss in cash flow exceeding $2 billion and 20+% return on equity, and the company’s transition narrative appears to be intact.

Constructive outlooks break through the noise

Wall Street still leans bullish on TEVA stock. Piper Sandler, Goldman Sachs, Barclays, and Truist have all raised their targets, with consensus around $38-$41. The average rating sits in “outperform” territory.

But there are some obvious potential risks. In addition to a debt-to-equity ratio near 1.9, sentiment has been dented by insider selling, competitive pressure from the generic market, and regulatory uncertainty.

More than half of TEVA shares are institutionally owned, so large investors are staying engaged for now. As its turnaround story progresses, however, the next phase of the trend will be decided by evidence of sustained earnings growth … or the lack thereof.